Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris’ DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. It is also engaged in research and development of ComASUR, a delivery system that allows accurate valve placement, and the manufacturing and selling of proprietary ADAPT regenerative tissue products. The company generates a majority of its revenue from the United States and the rest from Switzerland and Australia.